September 16, 2014
The US Food and Drug Administration has approved AstraZeneca’s Movantik for opioid-induced constipation in adults with chronic non-cancer pain.
Movantik (naloxegol), an oral once-a-day treatment licensed from Nektar Therapeutics, belongs to a class of drugs called peripherally-acting mu-opioid receptor antagonists, which are used to decrease the constipating effects of opioids. The drug’s safety and effectiveness were established in two trials of 1,352 participants who had taken opioids for at least four weeks for non-cancer related pain and had opioid-induced constipation.
Read more at: http://www.pharmatimes.com/Article/14-09-16/FDA_approves_AstraZeneca_s_constipation_drug_Movantik.aspx#ixzz3DdGiFse8
Filed under: FDA 2014 Tagged: Approves, ASTRAZENECA, chronic non-cancer pain, constipation, fda, FDA 2014, Movantik, naloxegol, Nektar Therapeutics, opioid-induced constipation, receptor antagonists, US Food and Drug Administration
